SUMMARY:

• The debate around Biogen’s Alzheimer’s drug continues to rage.
• The clinical evidence supporting the approval of the drug is at best “weak.”
• How could the FDA approve a drug with such poor clinical data?
• How can Biogen’s employees continue to work for a company that is raping taxpayers for a drug that doesn’t work?